Home » Stocks » CRTX

Cortexyme, Inc. (CRTX)

Stock Price: $37.36 USD 5.70 (18.00%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
Pre-market: $38.30 +0.94 (2.52%) Jan 27, 7:29 AM
Market Cap 1.10B
Revenue (ttm) n/a
Net Income (ttm) -68.67M
Shares Out 29.49M
EPS (ttm) -2.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $37.36
Previous Close $31.66
Change ($) 5.70
Change (%) 18.00%
Day's Open 31.81
Day's Range 31.73 - 38.75
Day's Volume 582,251
52-Week Range 27.78 - 72.51

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 day ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerativ...

Seeking Alpha - 2 weeks ago

CRTX thinks that a bacteria causes Alzheimer's, and it has research to back up that hypothesis. A Phase 3 trial will yield toppling data in Dec 2021, and they have enough cash.

Zacks Investment Research - 2 weeks ago

Investors need to pay close attention to Cortexyme (CRTX) stock based on the movements in the options market lately.

Business Wire - 1 month ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerativ...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Cortexyme (CRTX) stock based on the movements in the options market lately.

Business Wire - 2 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerativ...

Business Wire - 2 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerativ...

Business Wire - 3 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerativ...

Business Wire - 4 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX) today announced that its GAIN Trial for Alzheimer’s disease (AD) has exceeded its enrollment target of 570 patients...

Business Wire - 4 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with A...

Business Wire - 6 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.

24/7 Wall Street - 7 months ago

The 2020 year is practically halfway done, and this has really been the year of the biotech.

Other stocks mentioned: ACAD, BIIB, BTAI, ITCI, NBIX, SAGE, ZYNE
Seeking Alpha - 7 months ago

Cortexyme: A New Approach To Defeat Alzheimer's Disease

The Motley Fool - 11 months ago

A promising new approach could potentially yield a new drug providing hope for millions of Alzheimer's patients worldwide.

Forbes - 1 year ago

Cortexyme (NASDAQ: CRTX) is a clinical stage bio-pharmaceutical company working on Alzheimer’s and other degenerative diseases. The company currently has one molecule in its pipeline, called C...

ETF Trends - 1 year ago

Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for inve...

Other stocks mentioned: BYND, IGMS, INMD, KRTX, NXTC, PLMR, SWAV, TPTX
Zacks Investment Research - 1 year ago

2019 was one of the busiest years for IPOs, and the calendar was packed with big tech unicorns and popular consumer brands. Here are some of the hottest market debuts we saw this year.

Other stocks mentioned: BYND, LYFT, RVLV, UBER

About CRTX

Cortexyme, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Industry
Biotechnology
IPO Date
May 9, 2019
CEO
Casey C. Lynch
Employees
23
Stock Exchange
NASDAQ
Ticker Symbol
CRTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Cortexyme stock is "Buy." The 12-month stock price forecast is 75.75, which is an increase of 102.76% from the latest price.

Price Target
$75.75
(102.76% upside)
Analyst Consensus: Buy